何氏眼科 reported revenue of ¥0.59B for the period ended 2026-06-30, +4.5% year on year. Net income was ¥0.04B, a 7.1% net margin on a 43.0% gross margin. The largest revenue line is 视光服务 at 28% of the total. Free cash flow for the period was ¥0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.59B | +4.5% |
| Gross profit | ¥0.25B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.04B | -5.0% |
| Gross margin | 43.0% | Net margin 7.1% |
| Revenue Q/Q | -8.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 视光服务 | ¥0.17B | 28.4% |
| 屈光不正手术矫正服务 | ¥0.16B | 27.0% |
| 非手术治疗 | ¥0.12B | 21.3% |
| 白内障诊疗服务 | ¥0.07B | 12.2% |
| 玻璃体视网膜诊疗服务 | ¥0.04B | 7.4% |
| 其他眼病诊疗服务 | ¥0.02B | 3.0% |
| 其他业务收入 | ¥0.00B | 0.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.33B | 57.0% |
| R&D | ¥0.01B | 1.6% |
| SG&A | ¥0.19B | 32.3% |
| Tax & other | ¥0.02B | 3.0% |
| Item | Amount |
|---|---|
| Total assets | ¥2.20B |
| Total liabilities | ¥0.29B |
| Shareholders' equity | ¥1.91B |
| Equity / assets | 86.8% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.02B |
| Cash conversion (OCF / net income) | 239% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
鸿铭股份 ・ 骏成科技 ・ 瑜欣电子 ・ 洁雅股份 ・ 军信股份 ・ 青木科技 ・ 粤万年青 ・ 信邦智能 ・ 雅艺科技 ・ 联检科技 ・ 益客食品 ・ 佳缘科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies